Cytokinetics (CYTK) FY2021 results: revenue $70 million, up 26.2% on the year
Cytokinetics Inc. (CYTK) reported revenue of $70 million for fiscal 2021, the year ended 31 December 2021, up 26.2% on the year before. Net income was -$215 million, and diluted earnings per share $-2.80. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2022.
Revenue
$70 million
+26.2% on the year
FY2014FY2021
Operating margin
-264.5%
-168.3% a year earlier
FY2014FY2021
Net income
-$215 million
FY2014FY2021
Diluted EPS
-$2.80
FY2014FY2021
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
-143
8.9
-90.9
Capital expenditure
48.9
11.1
2.6
+342.2%
Free cash flow
-191
-2.1
-93.5
Free cash flow margin
-271.8%
-3.8%
-348.1%
Cash from investing
-148
-197
-74.7
Cash from financing
320
234
160
+36.7%
Depreciation and amortisation
2.3
1.8
1.3
+24.3%
Share-based compensation
26.8
17.6
10.8
+52.3%
Diluted shares, weighted
77m
65m
n/a
+19.2%
Shares outstanding at period end
85m
71m
59m
+19.4%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
244
113
-10.9
+115.1%
Debt
143
136
129
+5.3%
Operating lease liabilities
112
0.4
2.2
+25,406.6%
Other liabilities
342
284
169
+20.4%
Total liabilities and equity
841
534
290
+57.6%
Fixed assets
73.3
13.3
4.5
+449.0%
Investments
511
418
231
+22.2%
Cash and equivalents
113
83.0
36.4
+35.8%
Receivables
51.8
4.4
5.2
+1,072.4%
Other assets
92.5
15.0
12.4
+516.0%
Total assets
841
534
290
+57.6%
10-K for the year ended 31 December 2021, filed 25 February 2022: the filing.